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Betahistine in the treatment of tinnitus in patients with vestibular 
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Betahistine is a medicine used to treat vestibular disorders that has also been used to treat tinnitus. 
Aim: To assess the effects of betahistine on tinnitus in patients with vestibular disorders. 
Material and method: Retrospective data were collected from patient records for individuals 
presenting with vestibular dysfunction and tinnitus. Patients included had received betahistine 48 
mg/day and clinical outcomes were compared with a control group comprising individuals who 
were unable to receive betahistine due to gastritis, ulcers, pregnancy, asthma or hypersensitivity to 
the drug. Patients underwent control of any aggravating factors and also standard vestibular exercises 
as a basis for treatment. The intensity, frequency and duration of tinnitus were assessed on the first 
day of dosing and after 120 days of treatment. Clinical improvement was defined as a total or partial 
reduction of tinnitus after treatment. 
Results: Clinical improvement was observed in 80/262 (30.5%) of patients treated with betahistine 
and 43/252 (17.1%) of control patients. Betahistine significantly (p<0.0001) improved tinnitus in 
treated individuals. 
Conclusion: The daily dosage of 48 mg of betahistine during 120 consecutive days is useful to 
reduce or eliminate tinnitus in patients with vestibular disorders.
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INTRODUCTION
Tinnitus, the perception of a sound in the absen-
ce of an apparent acoustic stimulus, is a growing health 
concern in all layers of the population. Estimates indicate 
that about 10%-15% of the population may have tinnitus. 
Adults and children may be affected, the prevalence of 
tinnitus increases with age and there is a high incidence 
associated with noise exposure such as age-related hea-
ring loss. Although we still need to better understand its 
pathophysiology, tinnitus could be the result of a spon-
taneous and aberrant neural activity at any level of the 
hearing system1.
Approximately 8% of individuals with tinnitus are 
severely handicapped by this anguishing symptom; in 
2,800 patients with tinnitus there was a significant asso-
ciation (p<0.05) between the symptom and the reduction 
in quality of life2. There is no influence from gender, age 
and hearing loss concerning the tinnitus nuisanse3.
Subjective tinnitus is a common symptom, with 
many causes4. One epidemiologic study showed that the 
most common cause for tinnitus was noise-induced hearing 
loss (37.8% of the cases); notwithstanding, many cases may 
be associated with other disorders, such as pain, stress, de-
pression and headaches caused by migraine5. Ear disorders, 
especially the ones happening together with conductive 
or sensorineural hearing loss, such as excessive exposure 
to intense noise, presbycusis, metabolic  disorders, oto-
toxic agents, Ménière’s disease, vestibular schwannoma 
and psychological disorders are among the most frequent 
causes6. Tinnitus may also happen in patients with normal 
audiometry; normal-hearing patients with tinnitus have 
clinical characteristics which are similar to those of pa-
tients with hearing loss; however, the age range affected 
and the impact on concentration and emotional balance 
were significantly lower7. In elderly patients, in whom 
the main finding upon audiometry was presbycusis, no 
correlation was found between the degree of hearing loss 
and the extent to which the patient was unhappy with 
the tinnitus8. Tinnitus is one of the classical symptoms of 
Ménière’s disease, a condition associated with substantial 
loss in quality of life9.
Tinnitus treatment is as diversified as the origin of 
the condition itself. Apparent causes must be treated. Con-
trolling the cause may not be enough to reduce or even 
eliminate the tinnitus. With varying degrees of success, 
different treatments have been proposed for the tinnitus, 
such as tinnitus retraining therapy, sound masking, hearing 
aid fitting, acupuncture and drug therapy.
Numerous pharmaceutical options have been 
investigated10-12, with different degrees of quality of life 
improvement and symptom relief1-2,13. Drugs tried were: 
membrane stabilizers (lidocaine chlorhydrate), anti-seizure 
agents (carbamazepine, gabapentin), antidepressants (fluo-
xetine chlorhydrate; sertraline chlorhydrate), anxiolytics 
(clonazepam, alprazolam), Ginkgo biloba 761 extract, 
vasomodulators (flunarizine, cinnarizine and betahistine); 
the time of use for each drug and the criterion of choice 
depends on the clinical characteristics of each patient14.
There are studies showing that betahistine may 
provide symptom relief for tinnitus15-18. Betahistine is an 
H3 antagonist bloodreceptor and an H1 agonist receptor 
which improves inner ear microcirculation19, promoting 
and facilitating central vestibular compensation20-22. It is 
currently recommended to treat symptoms from many 
vestibular disorders23-24, including tinnitus. Possible adver-
se events arising from betahistine use include headache, 
and epigastric discomfort. Betahistine is contraindicated 
in patients with gastrointestinal ulcers, asthma, pheochro-
mocytoma and hypersensitivity to the drug23.
The goal of the present study was to assess the 
effects of betahistine on tinnitus in patients with vestibular 
dysfunction.
METHODS
This was a case-controlled, retrospective and ex-
perimental study, carried out in a university facility. We 
retrospectively collected data from 865 patients with ages 
above 18 years who had tinnitus and peripheral vestibu-
lar dysfunction. The study was approved by the Ethics in 
Research Committee of the University where it was carried 
out, under protocol # 0117/08.
Patients were submitted to a neurotological evalu-
ation which included clinical history; ear, nose and throat 
exam, audiological and vestibular assessments. Hearing 
was assessed by means of the tonal audiometry, speech 
recognition and acoustic immittance tests. Auditory proces-
sing, brainstem audiometry and/or electrocochleography 
were eventually carried out. Body balance assessment in-
cluded the Romberg and Unterberger-Fukuda tests, positio-
nal and positioning nystagmus and electrocochleography.
We included patients with a diagnosis of peripheral 
vestibular disorders. We took off the study those patients 
with central nervous system disorders and those who 
did not conclude the treatment, or those who used other 
anti-dizziness medication or tinnitus-causing drugs. The 
patients who could use betahistine made up the study 
group, while the control group had those patients who 
could not use the drug for numerous reasons, including 
severe gastritis, ulcer, pregnancy, asthma and hypersen-
sitivity to the drug.
The study group patients received 48 mg/day of 
betahistine dichlorohydrate BID or TID during 120 days. 
All patients controlled worsening factors and did vesti-
bular rehabilitation exercises as base treatment. With the 
goal of homogeneously comparing the clinical results 
between control and treatment groups, a random sample 
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of patients from the study group was chosen in order to 
have a similar number of individuals in each group for 
statistical purposes.
The patients were observed in the beginning and 
four months into therapy. The patient’s overall impression 
was used as a variable to assess treatment efficacy. Effecti-
veness was assessed according to the patient’s subjective 
response at the end of treatment. Efficacy assessment 
was done by means of the following classification: 1 = 
complete improvement (symptom-free patient), 2 = very 
good improvement, 3 = good improvement, 4 = mild im-
provement and 5 = no improvement. Patients with very 
good improvement, good improvement and mild impro-
vement were included in the improvement class (partial 
improvement). Tolerability was judged by the investigators 
and the patient at the end of treatment. The chi-squared 
test was utilized in order to statistically compare tinnitus 
clinical improvement between the treatment and control 
groups. The significance level was 5% (α= 0.05). Statistical 
analyses were carried out using the SPSS 10.0 for Windows 
(Statistical Package for Social Sciences, version 10.0, 1999).
RESULTS
We had a total of 613 (70.9%) patients in the study 
group and 252 (29.1) in the control group. Clinical im-
provement was seen in 202 (32.8%) patients in the study 
group and in 43 (17%) patients in the control group, as 
per depicted in Figure 1. In order to compare the clinical 
results of tinnitus between the groups, a random sample 
of 42.7% patients in the study group (n=262) was selected 
in order to provide for a similar number of individuals 
from the study and from control for analysis purposes 
(Figure 2). A total of 514 patients made up the series in 
the present study. The experiment group was made up of 
262 patients (51.0%), with ages varying between 19 and 
76 years (mean value of 54.5 years); 160 females (61.1%) 
and 102 (39.9%) males; and the control group was made 
up of 252 patients (49.0%), with ages varying between 22 
and 79 years (mean of 56.0 years); 156 females (62.4%) 
and 90 (37.6%) males. We did not notice any differen-
ce between the study and control groups as far as the 
number of treated cases was concerned, nor in regards 
to age and gender. We noticed clinical improvement in 
80/262 (30.5%) patients treated with betahistine and in 
43/252 (17.1%) patients in the control group (Table 1). 
There was a statistically significant difference (p<0.0001) 
between results from the control and study groups as far 
as the number of patients who improved is concerned, 
thus showing betahistine efficacy in symptom remission 
or tinnitus cure in patients with vestibular dysfunction.
Treatment with betahistine was well tolerated, with 
low incidence of mild and transitional adverse effects, such 
as headaches, epigastric discomfort and dyspepsia. It was 
not necessary to break the use of the drug in any of the 
patients who suffered adverse effects.
DISCUSSION
Betahistine is currently utilized in the treatment of 
numerous vestibular disorders24. In a review about the 
effects of betahistine in patients with Ménière’s disease, 
some studies showed results which were considered sa-
tisfactory to reduce vertigo and tinnitus; and one study 
showed that betahistine did not have any effect on tinnitus 
when compared to placebo15. More recent clinical studies 
have shown that betahistine is efficient in the treatment of 
Ménière’s disease symptoms9,25-26. Findings from the present 
study have also shown betahistine activity in reducing 
tinnitus in patients with vestibular disorders. A significant 
clinical improvement (p<0.0001) was seen in 30.5% of the 
Figure 1. Comparing tinnitus clinical improvement among patients 
from the study and the control groups.
Figure 2. Comparing tinnitus clinical improvement between a random 
sample from the study and the control groups.
Table 1. Number of patients per response class
Response class Betahistine Control
1 = complete improvement 18 3
2 = very good improvement 21 8
3 = good improvement 26 12
4 = mild improvement 15 20
5 = no improvement 182 209
 262 252
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patients treated with betahistine, when compared to 17.1% 
of patients who improved in the control group.
Other studies have also reported tinnitus impro-
vement with the use of betahistine. In Ménière’s disease 
patients there was  tinnitus reduction with betahistine 
dimesylate (36 mg/day), as well as with a combination of 
20 mg of cinnarizine and 40 mg of dimenhydrinate, and 
there was not statistically significant difference between 
the two treatment groups27. In another study, the five-
week use of betahistine mesylate, in combination with B 
complex vitamin and diazepam significantly reduced tin-
nitus28. It is not possible to compare these findings, since 
the present investigation was carried out with betahistine 
dichlorohydrate and with different formulation and dosage.
Betahistine was not directly compared to other 
pharmacological approaches to treat tinnitus, thus it is 
difficult to estimate its efficacy when compared to other 
alternatives. Antidepressants are usually prescribed to treat 
tinnitus. There are reports regarding the use of fluoxetine 
and paroxetine; retrospective reviews with imipramine 
and selective inhibitors of serotonin reuptake; studies with 
amitriptyline and double-blind studies with trimipramine, 
nortriptyline, paroxetine and sertraline, compared to pla-
cebo. On the other hand, the literature also mentions that 
tinnitus may be an adverse effect of antidepressant drugs, 
such as phenelzine, amitriptyline, protriptyline, doxepin, 
imipramine, fluoxetine, trazodone, bupropion, venlafaxine. 
Tinnitus may also be associated with the interruption of 
antidepressant drugs such as venlafaxine and sertralina29-31.
The evidence concerning the pharmacological ap-
proaches to treat tinnitus is being built. The data from the 
present study suggests that betahistine can be a useful and 
well tolerated treatment option to be considered. We did 
not find other studies comparing patients with tinnitus and 
peripheral vestibular syndromes. We still need controlled 
prospective studies in order to confirm the present results.
CONCLUSION
The 48 mg/day dose of betahistine during 120 
consecutive days is useful to reduce or eliminate tinnitus 
in patients with vestibular disorders.
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